

08 May 2024

ASX Announcement


First \$A9M sales month and \$A10M revenue month

The Company is pleased to announce record monthly revenue of \$A10.1m (unaudited) for April 2024.

Highlights:

- The U.S. business grew strongly, with monthly sales of \$A6.9m (unaudited), up circa 75.0% on STLY.
- Rest of World had monthly sales of \$A2.4m (unaudited), up circa 68.2% on STLY. Strong growth continues in the UK/I, ANZ, Hong Kong, and Germany.
- Total group revenue for the month, including BARDA was \$A10.1m (unaudited), up circa 68.6% on STLY.

\$A monthly milestones



Chair, David Williams said: *“Rest of World sales are very pleasing, coming off a low base. The direction is clear, and with new geographies and new patient applications I couldn’t be happier. It’s hard to contain my excitement when I see first time orders into Turkey, Abu Dhabi and Ukraine as I think of the lives we are saving.”*

CEO, Swami Raote said: *“We are grateful for the manner in which clinicians are helping us with insights, innovation, education and adoption beyond difficult burns to other areas in plastic and reconstructive surgery. Our global impact continues to accelerate, with 42,000+ patients treated across 39 countries.”*

This announcement has been authorised by PolyNovo General Counsel & Company Secretary, Lior Harel.

About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care that designs, develops, and manufactures dermal regeneration solutions (NovoSorb® BTM, NovoSorb® MTX) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information see polynovo.com

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb’s unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

Further information:

David Williams
Chairman
Mobile: + 61 414 383 593

Swami Raote
CEO
Mobile: +61 (0) 3 8681 4050